ALX Oncology Holdings Inc. (ALXO) key performance indicators and operating metrics (3 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Loss (Non-GAAP) | -15.35M | FY2026-Q1 |
| Cash, Cash Equivalents, and Investments | 67M | FY2025-Q3 |
| Overall Response Rate (CD47-Low Retained HER2-Positive Gastric Cancer Subgroup) | 37.50 percent | FY2025-Q3 |
Back to ALXO overview · ALXO earnings · ALXO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.